A B S T R A C T A proteolytic procoagulant has been identified in extracts of human and animal tumors and in cultured malignant cells. It directly activated Factor X but its similarity to other Factor X-activating serine proteases was not clear. This study describes work done to determine whether this enzyme, cancer procoagulant, is a serine or cysteine protease. Purified cancer procoagulant from rabbit V2 carcinoma was bound to a p-chloromercurialbenzoate-agarose affinity column and was eluted with dithiothreitol. The initiation of recalcified, citrated plasma coagulation activity by cancer procoagulant was inhibited by 5 mM diisopropylfluorophosphate, 1 mM phenylmethylsulfonylfluoride, 0.1 mM HgCl2, and 1 mM iodoacetamide. Activity was restored in the diisopropylfluorophosphate-, phenylmethylsulfonylfluoride-, and HgCl2-inhibited samples by 5 mM dithiothreitol; iodoacetamide inhibition was irreversible. Russell's viper venom, a control Factor Xactivating serine protease, was not inhibited by either 0.1 mM HgCl2 or 1 mM iodoacetamide. The direct activation ofFactor X by cancer procoagulant in a two-stage assay was inhibited by diisopropylfluorophosphate and iodoacetamide. Diisopropylfluorophosphate inhibits serine proteases, and an undefined impurity in most commercial preparations inhibits cysteine proteases. Hydrolysis of diisopropylfluorophosphate with CuS04 and imidazole virtually eliminated inhibition of thrombin, but cancer procoagulant inhibition remained complete, suggesting that cancer procoagulant was inhibited by the undefined impurity. These results suggest that cancer procoagulant is a cysteine endopeptidase, which distinguishes it from other coagulation factors including tissue factor. This and other data suggest that neoplastic cells produce this unique cysteine protease which may initiate blood coagulation.
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INTRODUCTION
Factor X is the point of confluence of the intrinsic and extrinsic pathways in the coagulation cascade. Factor X Received for publication 6 October 1980 and in revised form 8 January 1981. is converted to its activated form (Factor Xa) by the proteolytic removal of an activation glycopeptide with a molecular weight of -11,000 (1, 2) . This activation can be facilitated by either Factors IXa and VIII, Factor VIIa and tissue factor, the autolytic conversion by Factor Xa, or by an enzyme in the venom of Vipera Russelli (Russell's viper venom) (1-4). The active component within all of these Factor X-activating systems is a serine protease (1) (2) (3) (4) (5) . In addition, Factor X can be activated by other serine proteases such as trypsin (1, 2, 6) , cathepsin C (7), and the plant cysteine protease, papain (8) .
Increased vascular thrombosis and the deposition of fibrin associated with malignant disease led us to look for an abnormal coagulation factor associated with neoplastic tissue. A proteolytic enzyme, cancer procoagulant, has been purified from rabbit V2 carcinoma and some of its physical, chemical, and enzymatic properties have been determined.' In addition, cancer procoagulant activity has been identified in extracts of several human malignant tumors (9) and in cultured malignant cells2 (10) (11) (12) (13) Citrated bovine and human plasma were obtained fresh and prepared as described previously (14) for use in the singlestage recalcified coagulation time assay. Pure bovine Factor X was kindly provided by Dr. Earl Davie and used in the twostage clotting assay as described previously (14) . Russell's viper venom (Sigma Chemical Co.) was used as a control Factor X-activating serine protease. Partially purified bovine thrombin (Parke Davis and Co., Detroit, Mich.) was diluted to 0.1 U/ml in 10 mM veronal-buffered saline (pH 7.6).
Methods. General: Cancer procoagulant was purified from rabbit V2 carcinoma tumor tissue.4 Briefly, tumor tissue was removed surgically before the animal's death, extracted in three changes of 20 mM veronal buffer (pH 7.8) for 3 h each, and the pooled extracts were concentrated about 10-fold over a PM-10 ultrafiltration membrane. The concentrated extract was applied to a benzamidine affinity chromatography column, unbound protein was washed from the column with 10 mM veronal buffer (pH 7.9) containing 1 mM EDTA and 50 mM NaCl, and the bound protein was eluted with 1.0 M propionic acid. After neutralizing the propionic acid with NaOH, the sample was concentrated on a PM-10 ultrafiltration membrane, dialyzed, and applied to a 1.5-agarose gel filtration column. The high molecular weight, included protein peak containing the procoagulant activity was reapplied to a benzamidine affinity resin, the unbound protein was washed from the column with 10 mM veronal buffer, adsorbed protein was eluted with 0.1% Triton X-100, and then the bound protein was eluted with 0.5 M propionic acid. After neutralizing and removing the propionic acid by dialysis, the concentrated sample was applied to a phenyl-Sepharose hydrophobic affinity column and the purified procoagulant was eluted with 10% dimethyl sulfoxide. The purified procoagulant sample was homogeneous by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. At each step ofthe purification the procoagulant activity was assayed by measuring the recalcified coagulation time of citrated plasma (14) and its protein concentration with a modified Lowry method (15) . Its sensitivity to DFP and its activity in Factor VIIdepleted bovine plasma (14, 16) 4 Gordon, Stuart G. Manuscript submitted for publication.
The protein peaks were collected separately and concentrated -10-fold on a PM-10 ultrafiltration membrane and dialyzed against MES buffer to remove the DTT. These samples were assayed for protein and procoagulant activity as described above. Inhibition studies. Samples purified by the method described above and those obtained from the PCMB affinity column were tested for their inhibition by 5 mM DFP, 1 mM PMSF, 1 mM iodoacetamide, and 0.1 mM HgCl2. In each case, samples ofcancer procoagulant were assayed for procoagulant activity by measuring the single-stage recalcification clotting time of citrated human plasma with a fibrometer. The percent decrease in the clotting time of samples containing cancer procoagulant or controls compared to the appropriate 25 mM MES buffer blank was used to quantify coagulant activity. Russell's viper venom was used as a coagulation control and as a Factor X-activating serine protease control. Portions of the samples and controls were treated with the appropriate inhibitors, incubated for 30 min at 37°C, and reassayed for procoagulant activity. Portions of each sample were made 5 mM with DTT, incubated overnight at 5°C, dialyzed for 3 h against two changes of 25 mM MES buffer, and reassayed for procoagulant activity to determine if the inhibition had been effectively reversed by the reducing agent. In all studies, the activity ofthe untreated samples was compared with the same sample after inhibition and reactivation by a paired t-test analysis.
To determine whether cancer procoagulant was inhibited by DFP or by the conjectured impurity of DFP, samples of DFP were treated with cupric ion and imidazole to catalyze the hydrolysis of DFP (17) and tested for their inhibitory capacity at various times during the hydrolysis reaction (18) . A solution of25 mM CuSO4 and 25 mM imidazole was prepared in water, adjusted to pH 7.6 with 1 N NaOH, and made 10 mM DFP by the addition of 0.5 M DFP in isopropanol. The reaction mixture was incubated at 37°C for 2 h with constant stirring. Samples (0.2 ml) of the reaction mixture were taken at 0, 60, and 120 min, pH was adjusted to 7.6, and 20 ,ul of 250 mM EDTA was added to stop the hydrolysis of DFP. A sample (0.1 ml) of thrombin or cancer procoagulant was mixed with an equal volume of the EDTA-treated reaction mixture, incubated for 30 min at 37°C, and assayed by measuring the recalcified clotting time as described above. Control thrombin, cancer procoagulant and buffer blank samples were mixed with the same amounts of CuSO4, imidazole, and EDTA, but containing isopropanol without DFP to determine the effect of these ingredients on the clotting assay.
The direct activation ofFactor X. A two-stage coagulation assay was used, as described previously (14) , to confirm that the protein eluted from the PCMB column and sensitive to the inhibitors could directly activate Factor X. In brief, purified bovine Factor X was incubated with either cancer procoagulant or Russell's viper venom in the first stage of the clotting assay. Samples were removed from the first stage and added to Factor VII-and Factor X-deficient bovine plasma (Sigma Chemical Co.) and the recalcified clotting time of the second stage was measured with a fibrometer. Both inhibited and uninhibited samples were assayed for their ability directly to activate Factor X. The results are expressed as the normalized clotting time of the second stage of the assay. RESULTS PCMB-affinity chromatography. A partially purified V2 carcinoma extract sample containing cancer procoagulant was applied to the PCMB affinity column (Fig. 1) A small amount of procoagulant activity was eluted in 0.1 mM DTT with the major peak of activity in the 5 mM eluate. Inhibition studies. Studies of the inhibition characteristics of purified cancer procoagulant were performed in an effort to determine whether it was a serine or cysteine protease. Purified cancer procoagulant was treated with 5 mM DFP, 1 mM PMSF, 0.1 mM HgCl2, and 1 mM iodoacetamide. The inhibited samples were assayed for procoagulant activity (Table I) . Treatment of the inhibited enzyme with 5 mM DTT effectively reactivated samples inhibited with DFP, PMSF, and HgCl2. lodoacetamide inhibition was irreversible.
Russell's viper venom, the control Factor X-activating serine protease, was treated with 0.1 mM HgCl2 and 1 mM iodoacetamide. It was not inhibited by either HgCl2 or iodoacetamide.
To determine whether iodoacetamide treatment might denature cancer procoagulant rather than block its active site, a PMSF-treated sample was made 1 mM with iodoacetamide and then treated with 5 mM DTT, dialyzed, and analyzed for activity. There was no procoagulant activity after treatment with PMSF or after iodoacetamide treatment, but full activity was recovered after reductive DTT reactivation. A similar double inhibition was performed to determine whether DFP and iodoacetamide reacted at the same site on the enzyme. A DFP-inhibited sample was made 1 mM with iodoacetamide and then reactivated with 5 mM DTT. There was no clotting activity after DFP and iodoacetamide treatment but reactivation with DTT facilitated recovery offull activity, whereas the inhibition of the control cancer procoagulant sample, treated with iodoacetamide alone, was irreversible.
Cupric ion and imidazole catalyze the hydrolysis of DFP with the release of hydrofluoric acid (17) ; in these experiments the decrease in pH confirmed that the reaction was proceeding. In four experiments, the clotting time of the untreated thrombin control and the purified cancer procoagulant sample was 112±4 and 130±8 s, respectively, after normalizing the results to a 200-s blank time. Thrombin and cancer procoagulant were treated with the DFP hydrolysis mixture immediately after it was prepared (0 min) and after 60 and 120 min incubations at 37°C. Thrombin activity decreased to 9±6% of its original clotting activity after reacting with the 0-min DFP hydrolyzate (Fig. 2 ). After treatment with the 60-and 120-min DFP hydrolyzate, thrombin activity was about 50 and 92% of its original level, respectively. In contrast, cancer procoagulant activity was almost completely inhibited after treatment with 0-, 60-, and 120-min DFP hydrolyzate. These results suggest that the inhibitor of thrombin was hydrolyzed by the CuSO4-imidazole reaction, whereas the cancer procoagulant inhibitor was not destroyed under these conditions.
To confirm that the procoagulant activity blocked by the inhibitors was activating Factor X as previously described (10), a two-stage clotting assay was performed. Both DFP and iodoacetamide effectively inhibited the activation of Factor X by cancer procoagulant in the first stage of the assay (Fig. 3) . lodoacetamide did not affect the activity of the Russell's viper venom control as expected.
A Factor X-activating Cysteine Protease from Malignant Tissue (20) , and cysteine proteases (thiol and sulfhydryl proteases) are more active between pH 5 and 7 (20, 21) , this observation suggested that cancer procoagulant might be a cysteine protease. This led us to study the effect of specific inhibitors on cancer procoagulant activity in an effort to determine whether cancer procoagulant was a serine or cysteine protease. Cysteine proteases are inhibited by PCMB and will bind to a PCMB ligand linked to agarose (22, 23) . The reasonably specific nature of the binding of cysteine proteases to a PCMB-agarose affinity column provides evidence suggesting that cancer procoagulant may be a cysteine protease. Free sulfydryl groups on other proteins will bind to a PCMB affinity resin (24, 25) , but the specificity and avidity of this binding may be less 5 Manuscript in preparation. than when the active site of an enzyme recognizes the PCMB ligand. The results demonstrate that cancer procoagulant binds to the PCMB affinity resin and is not eluted by 1 M urea and 1% Tween 20 with the other adsorbed proteins and is effectly removed with DTT, properties that are consistent with the concept that cancer procoagulant may be a cysteine protease.
One of the effective ways to distinguish between serine and cysteine proteases is to inactivate them selectively by means ofspecific inhibitors (20, 21) . DFP and PMSF are well-known irreversible inhibitors of serine proteases (20, 26, 27) ; PMSF is a less effective inhibitor of cysteine proteases, and is reversible (20, 21, 28) ; and the DFP inhibition of cysteine proteases is controversial, as discussed below. Iodoacetamide and mercury are more specific inhibitors for cysteine proteases and are less effective or even ineffective for the inhibition of serine proteases (20) (21) (22) (29) (30) (31) , ficin (18) , papain (32, 33) , and chymopapain (34, 35) . Although there is disagreement, the studies generally conclude that commercial DFP inhibits cysteine proteases but that the inhibition of the active site sulfhydryl is due to an undefined impurity in most commercial preparations. Purified DFP phosphorylates serine (18, 35) (18, (30) (31) (32) 35) , and the DFP impurity irreversibly inhibits the active site sulfhydryl (18, 31) . Since the evidence presented here suggested cancer procoagulant was a cysteine protease, it seemed likely that the inhibition by DFP, a consistent and reproducible observation (9, 10, 14) , was probably due to impurities in the commercial DFP preparations that were employed. To confirm this hypothesis, DFP was catalytically hydrolyzed to diisopropylphosphate and hydrofluoric acid. The conjectured DFP impurity is not hydrolyzed under these conditions, so that during the course of the reaction inhibition of serine proteases should decrease while inhibition of cysteine proteases should remain unchanged (18) . Inhibition of thrombin activity was almost complete when treated with the initial (0 min) DFP hydrolyzate mixture, but after 2 h the DFP hydrolyzate had lost virtually all of its ability to inhibit the clotting activity ofthis serine protease. In contrast, the inhibition of cancer procoagulant by the DFP hydrolyzate remained unchanged during the 2 h hydrolysis of DFP. Thus, all the data are consistent with the hypothesis that cancer procoagulant is a cysteine protease and its inhibition by DFP is due to an impurity in the Aldrich DFP used in this research.
DFP inhibition of cancer procoagulant activity was reversed by reductive reactivation with DTT. Although other investigators suggest that inhibition of cysteine proteases by the DFP impurity is essentially irreversible (18, 29, 31) , their data show partial (-10%) reactivation of bromelain with 5 mM cysteine (29) and about 40% reactivation of ficin with 0.25 M cysteine (18) . Our use of DTT, a more potent reducing agent than cysteine, different reactivation conditions, and the differences in the cysteine proteases may account for our more effective reactivation of DFPinhibited cancer procoagulant.
Russell's viper venom standard was used to compare the effect of these inhibitors on a serine protease that activates Factor X in a well-characterized manner (27, (36) (37) (38) . Mercury (0.1 mM) had little or no effect on the procoagulant activity of Russell's viper venom, which is consistent with the observations of others (38) ; and 1 mM iodoacetamide seemed to stimulate the activity of Russell's viper venom. Thus, there was a clear distinction between the effect of these inhibitors on the activity of cancer procoagulant and the serine protease in Russell's viper venom. These data strongly suggest that cancer procoagulant is a cysteine protease, but unequivocal evidence from an amino acid analysis demonstrating a chemically modified active site cysteine must await the purification of milligram amounts of the enzyme.
Several groups have suggested that malignant cells produce higher levels and possibly different types of cysteine proteases than normal cells (39, 40) . Evidence from several laboratories has suggested that malignant cells produce higher levels of "thromboplastic" coagulation factors than normal cells (41) (42) (43) , but clear definition of these factors has been difficult to obtain. Although there is evidence that suggests that malignant cells produce an abnormal coagulation activity that is not associated with normal cells (9-13),6 it has not been clear whether this is a known coagulation factor or whether it is something unique to the malignant state. This study suggests that a cysteine protease extracted from rabbit V2 carcinoma activates Factor X, an observation that distinguishes it from other coagulation enzymes.
